World Wires · story 29656 · unverified · 1 source(s)

CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advanci

Open in the desk

Coverage

What this site indexes